Comparison of azithromycin and oral hygiene program in the treatment of cyclosporine-induced gingival hyperplasia

Renal Failure

Volumn 29, Issue 3, 2007, Pages 265-270

  Ramalho, Vera L C ^a   Ramalho, Horácio J ^a   Cipullo, José P ^a   Azoubel, Reinaldo ^a   Burdmann, Emmanuel A ^a,b  

^a HOSPITAL DE BASE   (Brazil)

^b NONE   (Brazil)

Author keywords

Azithromycin; Cyclosporine; Gingival hyperplasia; Oral hygiene; Renal transplantation

Indexed keywords

AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN; REPLAK; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GENDER; GINGIVA BLEEDING; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; HALITOSIS; HEALTH PROGRAM; HUMAN; KIDNEY TRANSPLANTATION; MALE; MOUTH HYGIENE; PAIN; PERIODONTAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMBINED MODALITY THERAPY; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GINGIVAL HYPERPLASIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; ORAL HYGIENE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34248578994     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701263580     Document Type: Article

References (33)

1. De Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis. 1999;28:631-637.
2. Boltchi FE, Rees Terry D, Iacopino AM. Cyclosporine A induced gingival overgrowth: A comprehensive review. Quintessence Int. 1999;30:775-783.
3. Peters TG, Spinola KN, West JC, Aeder MI, Danovitch GM, Klintma, et al. Differences in patient and transplant professional perception immunosuppression-induced cosmetic side effects. Transplantation. 2004;78:537-543.
4. Fiebiger W, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. Health Qual Life Outcomes. 2004;2:2.
5. Meraw SJ, Sheridan PJ. Medically induced gingival hyperplasia. Mayo Clin Proc. 1998;73:1196-1199.
6. Seymour RA, Smith DG. The effect of a plaque control program on the incidence and severity of cyclosporine-induced gingival changes. J Clin Periodontol. 1991;18:107-110.
7. Somacarrera ML, Hernandez G, Acero J, Moskow BS. Factors related to the incidence and severity of cyclosporine-induced gingival overgrowth in transplant patients: A longitudinal study. J Periodontol. 1994;65:671-675.
8. Kantarci A, Cebeci I, Tuncer O, Carin M, Firatli E. Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. J Periodontol. 1999;70:587-593.
9. Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporine associated gingival hyperplasia with azithromycin therapy. N Engl J Med. 1995;332:753-754.
10. Nash MN, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation. 1998;65:1611-1615.
11. Gómez ME, Sánchez-Nuñes JE, Sánchez C, Corte S, Aguado C, Baltar PJ, et al. Treatment of cyclosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant. 1997;12:2694-2697.
12. Chand DH, Quattrocchi J, Poe SA, Terezhalmy GT, Strife CF, Cunn RJ. Trial of metronidazole vs. azithromycin for treatment of cyclosporine-induced gingival overgrowth. Pediatr Transplant. 2004;8:60-64.
13. Tokgoz B, Sari Hi, Yildiz O, Aslan S, Sipahioglu M, Okten T, et al. Effects of azithromycin on cyclosporine-induced gingival hyperplasia in renal transplant patients. Transplant Proc. 2004;36:2699-2702.
14. Greene JC, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc. 1964;68:7-13.
15. Angeolopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg. 1972;34:898-906.
16. Bokenkamp A, Bohnhorst B, Beier C, Albers N, Offner G, Brodehl J. Nifedipine aggravates cyclosporine A-induced gingival hyperplasia. Pediatr Nephrol. 1994;8:181-185.
17. Sefton AM, Maskell JP, Beighton D, Whiley A, Shain H, Foyle D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol. 1996;23:998-1003.
18. Romito GA, Lotufo RF, Saraiva L, Pustiglioni NA, Pustiglioni FE, Stolf NA. Superinfecting microorganisms in patients under treatment with cyclosporin-A and its correlation to gingival overgrowth. Pesqui Odontol Bras. 2003;17:35-40.
19. Worm HC, Wirnsberger GH, Mauric A, Holzer H. High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin. Nephrol Dial Transplant. 2004;19:1890-1894.
20. Wong W, Hodge MG, Lewis A, Sharpstone P, Kingswood JC. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole. Lancet. 1994;343:986.
21. Aufricht C, Hogan EL, Ettenger RB. Oral metronidazole does not improve cyclosporine A-induced gingival hyperplasia. Pediatr Nephrol. 1997;11:552-555.
22. Harikrishnan P, Harden PN. Tacrolimus can resolve cyclosporin-induced gingival hyperplasia. Nephrol Dial Transplant. 1999;14:1805-1806.
23. Yamada H, Nishimura F, Naruishi K, Chou H-H, Takashiba S, Albright GM, et al. Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol. 2000;71:955-960.
24. Bonnaure-Mallet M, Tricot-Doleux S, Godeau GJ. Changes in extracellular matrix macromolecules in human gingival after treatment with drugs inducing gingival overgrowth. Arch Oral Biol. 1995;40:393-400.
25. Arora PD, Silvestri L, Ganss B, Sodek J, McCulloch CA. Mechanism of cyclosporin-induced inhibition of extracellular collagen degradation. J Biol Chem. 2001;276:14100-14109.
26. Bulut S, Ozdemir BH, Alaaddinoglu EE, Oduncuoglu FB, Bulut OE, Demirhan B. Effect of cyclosporin A on apoptosis and expression of p53 and bcl-2 proteins in the gingiva of renal transplant patients. J Periodontol. 2005;76:691-695.
27. Saito K, Mori S, Iwakura M, Sakamoto S. Immunohistochemical localization of transforming growth factor B, basic fibroblast growth factor and heparan sulphate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontol. 1996;31:545-555.
28. Vieira Jr JM, Noronha IL, Malheiros DMAC, Burdmann EA. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-β expression with preserved renal blood flow. Transplantation. 1999;68:1746-1752.
29. Yoshida T, Nagata J, Yamane A. Growth factors and proliferation of cultured rat gingival cells in response to cyclosporin A. J Periodontal Res. 2005;40:11-19.
30. Wirnsberger GH, Pfragner R. Comment on "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman. Transplantation. 1999;67:1289-1291.
31. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Therap. 2000;292:156-163.
32. Jaffe A, Francis J, Rosenthal M, Bush A. Long term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998;351:420.
33. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet. 2002;360:978-984.